IDEXX Laboratories Stock News

IDEXX (IDXX) delivers better-than-expected earnings and revenues in the second quarter of 2023, backed by CAG Diagnostics' recurring revenue growth.

The headline numbers for Idexx (IDXX) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates a

Idexx Laboratories (IDXX) came out with quarterly earnings of $2.67 per share, beating the Zacks Consensus Estimate of $2.43 per share. This compares to earnings of $1.56 per share a year ago.

IDEXX Laboratories' (IDXX) second-quarter 2023 results are expected to reflect an impressive performance in the CAG segment.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

IDEXX Laboratories, a healthcare supplier specializing in veterinary health diagnostics and research, is a potential high-performing compounder due to its wide-moat business model, anti-cyclical custo

The continued solid demand for veterinary services and benefits from strong execution poise IDEXX (IDXX) well for future growth.

IDEXX's (IDXX) Cystatin B Test can help veterinary professionals to spot kidney damage before it affects kidney function, which may result in better patient outcomes.

Investing $10,000 into Apple, Nvidia, or Idexx Laboratories a decade ago would have netted you more than $100,000 today. Both Apple and Nvidia have some exciting next-gen growth opportunities to pursu

Investors continue to be optimistic about IDEXX (IDXX) on the strength of the Companion Animal Group business.

WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, will participate in the Stifel Jaws & Paws Conference on Wednesday, May 31, 20

Teladoc looks to transition from a high-flying growth story to a profitable enterprise. Doximity's early profitability and cash generation point to incredible potential ahead.

Continued solid demand for veterinary services and record global premium instrument placements drive IDEXX's (IDXX) Q1 revenues.

IDEXX Laboratories, Inc. (NASDAQ:IDXX ) Q1 2023 Earnings Conference Call May 2, 2023 8:30 AM ET Company Participants Jay Mazelsky - President and Chief Executive Officer Brian McKeon - Executive Vice

The headline numbers for Idexx (IDXX) give insight into how the company performed in the quarter ended March 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates